Breaking News Instant updates and real-time market news.

CERS

Cerus

$5.31 /

+0.11 (+2.12%)

16:05
05/05/20
05/05
16:05
05/05/20
16:05

Cerus backs FY20 product revenue view of $89M-$93M

The company expects 2020 product revenue to be in the range of $89 million to $93 million, unchanged from the prior guidance originally provided on January 13, 2020. The guidance range represents approximately 20% to 25% growth compared to 2019 reported product revenue.

  • 05

    May

  • 07

    May

  • 03

    Jun

CERS Cerus
$5.31 /

+0.11 (+2.12%)

02/26/20 BTIG
Cerus initiated with a Buy at BTIG
01/23/20 Cowen
Cowen encouraged by Cerus data on Intercept in light of new coronavirus
11/13/19 BTIG
Cerus upgraded to Buy from Neutral at BTIG
08/28/19
Fly Intel: Top five analyst initiations

TODAY'S FREE FLY STORIES

Initiation
Becton Dickinson initiated with a Buy at Goldman Sachs » 18:38
05/31/20
05/31
18:38
05/31/20
18:38
BDX

Becton Dickinson

$246.97 /

+5.47 (+2.27%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BDX Becton Dickinson
$246.97 /

+5.47 (+2.27%)

BDX Becton Dickinson
$246.97 /

+5.47 (+2.27%)

05/14/20 Piper Sandler
Becton Dickinson price target raised to $296 from $286 at Piper Sandler
04/08/20 Wells Fargo
Becton Dickinson price target lowered to $270 from $279 at Wells Fargo
03/04/20 Citi
Becton Dickinson initiated with a Neutral at Citi
03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
BDX Becton Dickinson
$246.97 /

+5.47 (+2.27%)

BDX Becton Dickinson
$246.97 /

+5.47 (+2.27%)

BDX Becton Dickinson
$246.97 /

+5.47 (+2.27%)

Downgrade
Abbott downgraded to Sell from Neutral at Goldman Sachs » 18:32
05/31/20
05/31
18:32
05/31/20
18:32
ABT

Abbott

$95.31 /

+3.23 (+3.51%)

Goldman Sachs analyst…

Goldman Sachs analyst Amit Hazan downgraded Abbott Laboratories to Sell from Neutral with a price target of $84, up from $79. The shares closed Friday up $2.82 to $94.95. The stock has overreacted to the company's COVID testing opportunity, Hazan tells investors in a research note. Despite taking an early lead with multiple viral and antibody emergency use authorizations in the U.S. and a "sizable" test production outlook, competitors have steadily diminished Abbott's early advantage with their own approvals on high throughput systems, says the analyst. Hazan sees 10% downside in the shares and remains skeptical that the demand for antibody testing will reach a material level for Abbott revenues given the much lower price point for those tests.

ShowHide Related Items >><<
ABT Abbott
$95.31 /

+3.23 (+3.51%)

ABT Abbott
$95.31 /

+3.23 (+3.51%)

04/20/20 Barclays
Abbott price target raised to $100 from $92 at Barclays
04/20/20 Barclays
Abbott price target raised to $100 from $92 at Barclays
04/17/20 Raymond James
Abbott price target raised to $102 from $92 at Raymond James
04/17/20 Credit Suisse
Abbott price target raised to $106 from $95 at Credit Suisse
ABT Abbott
$95.31 /

+3.23 (+3.51%)

ABT Abbott
$95.31 /

+3.23 (+3.51%)

ABT Abbott
$95.31 /

+3.23 (+3.51%)

ABT Abbott
$95.31 /

+3.23 (+3.51%)

Recommendations
Pebblebrook Hotel price target raised to $13 from $11 at Stifel » 18:21
05/31/20
05/31
18:21
05/31/20
18:21
PEB

Pebblebrook Hotel

$13.66 /

-0.44 (-3.12%)

Stifel analyst Simon…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PEB Pebblebrook Hotel
$13.66 /

-0.44 (-3.12%)

PEB Pebblebrook Hotel
$13.66 /

-0.44 (-3.12%)

04/24/20 BTIG
Pebblebrook Hotel, Host Hotesl upgraded to Buy from Neutral at BTIG
04/24/20 BTIG
Pebblebrook Hotel upgraded to Buy from Neutral at BTIG
04/07/20 Citi
Pebblebrook Hotel downgraded to Sell from Neutral at Citi
03/17/20 Stifel
Pebblebrook Hotel downgraded to Hold from Buy at Stifel
PEB Pebblebrook Hotel
$13.66 /

-0.44 (-3.12%)

PEB Pebblebrook Hotel
$13.66 /

-0.44 (-3.12%)

Hot Stocks
Alexion, Amgen reach settlement deal on patent challenge » 16:37
05/31/20
05/31
16:37
05/31/20
16:37
ALXN

Alexion

$120.03 /

+5.595 (+4.89%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

According to a…

According to a company's filing, "On May 28, 2020, Alexion Pharmaceuticals [ALXN] and Amgen [AMGN] entered into a Confidential Settlement and License Agreement to settle three inter partes review proceedings at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office initiated by Amgen that the Company previously disclosed. Pursuant to the Settlement Agreement, the company and Amgen have agreed to file a motion with the PTAB to terminate each of the pending IPRs. In addition, effective March 1, 2025 (or an earlier date in certain circumstances), the company grants to Amgen (and its affiliates and certain partners) a non-exclusive, royalty-free, license under U.S. patents and patent applications related to eculizumab and various aspects of the eculizumab product that the company currently markets and sells under the tradename SOLIRIS. This license will allow Amgen (and its affiliates and certain partners), effective March 1, 2025, the right to make, have made, use, import, have imported, sell, have sold, offer for sale, have offered for sale, distribute, and have distributed in or for the U.S., an eculizumab product." The foregoing description of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the Settlement Agreement, which the Company intends to file as an exhibit to a future current or periodic report.

ShowHide Related Items >><<
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

Periodicals
Amazon curbs operations, Apple keeps some stores closed, Bloomberg says » 16:22
05/31/20
05/31
16:22
05/31/20
16:22
AMZN

Amazon.com

$2,442.37 /

+42.04 (+1.75%)

, AAPL

Apple

$317.94 /

-0.38 (-0.12%)

, TGT

Target

$122.50 /

+4.055 (+3.42%)

Amazon (AMZN) scaled back…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TGT Target
$122.50 /

+4.055 (+3.42%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

05/27/20 Morgan Stanley
Amazon deal could open door for ridesharing competition, says Morgan Stanley
05/18/20 Bernstein
Amazon not building standalone overnight network, says Bernstein
05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
05/12/20 Barrington
Amazon interest in AMC 'not outside the realm of possibility,' says Barrington
AAPL Apple
$317.94 /

-0.38 (-0.12%)

05/28/20 JPMorgan
Apple price target raised to $365 from $350 at JPMorgan
05/27/20 BofA
Apple price target raised to $340 from $320 at BofA
05/27/20 Jefferies
Apple price target raised to $370 from $350 at Jefferies
05/27/20 Deutsche Bank
Apple price target raised to $320 from $305 at Deutsche Bank
TGT Target
$122.50 /

+4.055 (+3.42%)

05/21/20 Deutsche Bank
Target price target raised to $131 from $121 at Deutsche Bank
05/21/20 Nomura Instinet
Target price target raised to $135 from $121 at Nomura Instinet
05/21/20 BMO Capital
Target price target raised to $135 from $125 at BMO Capital
05/21/20 Barclays
Target price target raised to $135 from $120 at Barclays
TGT Target
$122.50 /

+4.055 (+3.42%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

TGT Target
$122.50 /

+4.055 (+3.42%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

TGT Target
$122.50 /

+4.055 (+3.42%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

TGT Target
$122.50 /

+4.055 (+3.42%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

Hot Stocks
BioMarin provides update from Phase 1/2 study of Valoctocogene Roxaparvovec » 16:18
05/31/20
05/31
16:18
05/31/20
16:18
BMRN

BioMarin

$106.67 /

+1.1 (+1.04%)

BioMarin Pharmaceutical…

BioMarin Pharmaceutical announced an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A. The data have been submitted as a late-breaking abstract to the World Federation of Hemophilia Virtual Summit to be held June 14-19, 2020. The four-year update for the 6e13 vg/kg and three-year update for the 4e13 vg/kg cohorts demonstrated that all subjects in both cohorts remain off prophylactic Factor VIII treatment since receiving their single dose of valoctocogene roxaparvovec. Cumulative mean annualized bleed rates remain less than one in both cohorts and below pre-treatment baseline levels. The mean ABR in year four for the 6e13 vg/kg cohort was 1.3, and the mean ABR in year three for the 4e13 vg/kg cohort was 0.5. Over the past year, six of the seven participants in the 6e13 vg/kg cohort and five of the six participants in the 4e13 vg/kg cohort remain free of spontaneous bleeds. Factor VIII activity levels declined commensurate with the most recent years' observations and remain in a range to provide hemostatic efficacy. Overall, the safety profile of valoctocogene roxaparvovec remains consistent with previously reported data with no delayed-onset treatment related events. No participants developed inhibitors to Factor VIII, and no participants withdrew from the study. No participants have developed thrombotic events. The most common adverse events associated with valoctocogene roxaparvovec occurred early and included transient infusion-associated reactions and transient, asymptomatic, and mild to moderate rise in the levels of certain proteins and enzymes measured in liver function tests with no long-lasting clinical sequelae. The Food and Drug Administration is reviewing the biologics license application, under Priority Review, for valoctocogene roxaparvovec with a PDUFA action date of August 21, 2020. The FDA also granted valoctocogene roxaparvovec Breakthrough Therapy designation. The European Medicines Agency validated the company's Marketing Authorization Application for valoctocogene roxaparvovec which has been in review under accelerated assessment since January. Recognizing valoctocogene roxaparvovec for its potential to benefit patients with unmet medical needs, EMA granted access to its Priority Medicines regulatory initiative. Although the MAA remains under accelerated assessment at this time, the company expects the review procedure to be extended by at least three months due to COVID-19 delays. Further, the company believes there is a high possibility that the MAA will revert to the standard review procedure, as is the case with most filings that initially receive accelerated assessment. Because of the combination of these events, the company expects an opinion from the Committee for Medicinal Products for Human Use in late 2020/early 2021. BioMarin's valoctocogene roxaparvovec has also received orphan drug designation from the FDA and EMA for the treatment of severe hemophilia A. The Orphan Drug Designation program is intended to advance the evaluation and development of products that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.

ShowHide Related Items >><<
BMRN BioMarin
$106.67 /

+1.1 (+1.04%)

BMRN BioMarin
$106.67 /

+1.1 (+1.04%)

05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
05/26/20 RBC Capital
BioMarin among Sanofi's most intriguing potential targets, says RBC Capital
05/22/20 Jefferies
Jefferies adds six names to Franchise Picks list, including BioMarin and TJX
05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
BMRN BioMarin
$106.67 /

+1.1 (+1.04%)

BMRN BioMarin
$106.67 /

+1.1 (+1.04%)

BMRN BioMarin
$106.67 /

+1.1 (+1.04%)

Periodicals
Nike releases 'Don't Do it' ad after George Floyd death, NY Post reports » 15:39
05/31/20
05/31
15:39
05/31/20
15:39
NKE

Nike

$98.47 /

+0.52 (+0.53%)

Nike is telling its fans…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NKE Nike
$98.47 /

+0.52 (+0.53%)

NKE Nike
$98.47 /

+0.52 (+0.53%)

04/28/20 BTIG
Nike initiated with a Buy at BTIG
04/28/20 Piper Sandler
Nike estimates lowered after Adidas results at Piper Sandler
04/14/20 OTR Global
Nike cancels some orders for low-priority retailers, says OTR Global
04/08/20 Piper Sandler
Piper lays out winners and losers in survey of 5,200 teens
NKE Nike
$98.47 /

+0.52 (+0.53%)

NKE Nike
$98.47 /

+0.52 (+0.53%)

NKE Nike
$98.47 /

+0.52 (+0.53%)

NKE Nike
$98.47 /

+0.52 (+0.53%)

Periodicals
Amazon removes racist messages on some product listings, Reuters reports » 13:46
05/31/20
05/31
13:46
05/31/20
13:46
AMZN

Amazon.com

$2,442.37 /

+42.04 (+1.75%)

, AAPL

Apple

$317.94 /

-0.38 (-0.12%)

Amazon (AMZN) said it was…

Amazon (AMZN) said it was removing certain images after messages using extremely strong racist abuse appeared on some listings on its U.K. website when users searched for Apple's (AAPL) AirPods and other similar products, according to Reuters. Reference Link

ShowHide Related Items >><<
AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

05/27/20 Morgan Stanley
Amazon deal could open door for ridesharing competition, says Morgan Stanley
05/18/20 Bernstein
Amazon not building standalone overnight network, says Bernstein
05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
05/12/20 Barrington
Amazon interest in AMC 'not outside the realm of possibility,' says Barrington
AAPL Apple
$317.94 /

-0.38 (-0.12%)

05/28/20 JPMorgan
Apple price target raised to $365 from $350 at JPMorgan
05/27/20 BofA
Apple price target raised to $340 from $320 at BofA
05/27/20 Jefferies
Apple price target raised to $370 from $350 at Jefferies
05/27/20 Deutsche Bank
Apple price target raised to $320 from $305 at Deutsche Bank
AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

Periodicals
KKR, Cinven, Providence seek to take over Masmovil, Bloomberg reports » 13:43
05/31/20
05/31
13:43
05/31/20
13:43
KKR

KKR

$27.81 /

-0.495 (-1.75%)

Three buyout funds are…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KKR KKR
$27.81 /

-0.495 (-1.75%)

KKR KKR
$27.81 /

-0.495 (-1.75%)

05/07/20 Oppenheimer
KKR price target lowered to $34 from $41 at Oppenheimer
04/21/20
Envision bankruptcy report has limited read-throughs, says Benchmark
04/17/20 BMO Capital
BlackRock price target raised to $441 from $386 at BMO Capital
04/15/20 Wells Fargo
KKR price target lowered to $33 from $38 at Wells Fargo
KKR KKR
$27.81 /

-0.495 (-1.75%)

KKR KKR
$27.81 /

-0.495 (-1.75%)

KKR KKR
$27.81 /

-0.495 (-1.75%)

KKR KKR
$27.81 /

-0.495 (-1.75%)

Periodicals
SpaceX Crew Dragon docks with International Space Station, Reuters says » 13:28
05/31/20
05/31
13:28
05/31/20
13:28
TSLA

Tesla

$834.23 /

+28.38 (+3.52%)

Just under 19 hours after…

Just under 19 hours after launching from Florida, SpaceX's Crew Dragon capsule carrying NASA astronauts Bob Behnken and Doug Hurley docked with the International Space Station on Sunday, marking the first U.S. space capsule to do so with a crew since 2011, according to Reuters. The launch on Saturday by SpaceX, the private rocket company of Tesla's Elon Musk, represented another milestone for the reusable rockets it pioneered to make spaceflight less costly and more frequent, the publication notes. Reference Link

ShowHide Related Items >><<
TSLA Tesla
$834.23 /

+28.38 (+3.52%)

TSLA Tesla
$834.23 /

+28.38 (+3.52%)

05/29/20
Fly Intel: Top five analyst initiations
05/29/20 Daiwa
Tesla initiated with an Outperform at Daiwa
05/28/20 Morgan Stanley
Tesla shift to software revenue key to unlocking bull case, says Morgan Stanley
05/27/20 Roth Capital
Tesla's North American price cuts hint at weak demand, says Roth Capital
TSLA Tesla
$834.23 /

+28.38 (+3.52%)

TSLA Tesla
$834.23 /

+28.38 (+3.52%)

TSLA Tesla
$834.23 /

+28.38 (+3.52%)

TSLA Tesla
$834.23 /

+28.38 (+3.52%)

TSLA Tesla
$834.23 /

+28.38 (+3.52%)

Periodicals
Airbus set to reassess output as virus shatters jet demand, Bloomberg says » 13:24
05/31/20
05/31
13:24
05/31/20
13:24
EADSY

Airbus

$0.00 /

+ (+0.00%)

Top Airbus executives are…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EADSY Airbus
$0.00 /

+ (+0.00%)

EADSY Airbus
$0.00 /

+ (+0.00%)

05/07/20 Barclays
Airbus price target lowered to EUR 68 from EUR 69 at Barclays
05/06/20 JPMorgan
Airbus price target lowered to EUR 51 from EUR 59 at JPMorgan
04/22/20 JPMorgan
Airbus price target lowered to EUR 59 from EUR 66 at JPMorgan
04/21/20 Morgan Stanley
Airbus price target lowered to EUR 71 from EUR 86 at Morgan Stanley
EADSY Airbus
$0.00 /

+ (+0.00%)

EADSY Airbus
$0.00 /

+ (+0.00%)

EADSY Airbus
$0.00 /

+ (+0.00%)

Periodicals
Amazon's Bezos invests in UK digital freight forwarder Beacon, Reuters says » 13:21
05/31/20
05/31
13:21
05/31/20
13:21
AMZN

Amazon.com

$2,442.37 /

+42.04 (+1.75%)

Amazon CEO Jeff Bezos has…

Amazon CEO Jeff Bezos has picked British startup Beacon, a digital freight forwarder, for his latest investment, Reuters' Maria Ponnezhath reports. Beacon said on Sunday it raised over $15M in Series A fundraising, from investors including Bezos, the author notes. Reference Link

ShowHide Related Items >><<
AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

05/27/20 Morgan Stanley
Amazon deal could open door for ridesharing competition, says Morgan Stanley
05/18/20 Bernstein
Amazon not building standalone overnight network, says Bernstein
05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
05/12/20 Barrington
Amazon interest in AMC 'not outside the realm of possibility,' says Barrington
AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

Hot Stocks
Karuna says KarXT superior to placebo in Phase 2 schizophrenia trial » 13:21
05/31/20
05/31
13:21
05/31/20
13:21
KRTX

Karuna Therapeutics

$94.26 /

+4.55 (+5.07%)

Karuna Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

13:13 Today Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
05/28/20 H.C. Wainwright
Karuna Therapeutics initiated with a Buy at H.C. Wainwright
05/08/20 Mizuho
Karuna Therapeutics price target raised to $116 from $103 at Mizuho
04/27/20 Oppenheimer
Karuna Therapeutics initiated with an Outperform at Oppenheimer
KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

Periodicals
Embraer negotiating $600M bank financing for exports, Reuters reports » 13:16
05/31/20
05/31
13:16
05/31/20
13:16
ERJ

Embraer

$5.52 /

+0.32 (+6.15%)

Embraer should obtain…

Embraer should obtain $600M in credit lines from Brazil's state development band BNDES and private banks in June, according to Reuters, citing government sources. The loans will finance production to meet demand for passenger planes and executive jets, sources said. Reference Link

ShowHide Related Items >><<
ERJ Embraer
$5.52 /

+0.32 (+6.15%)

ERJ Embraer
$5.52 /

+0.32 (+6.15%)

05/04/20 BofA
Embraer downgraded to Neutral from Buy at BofA
04/28/20 Credit Suisse
Embraer downgraded to Underperform from Neutral at Credit Suisse
04/27/20 Bradesco BBI
Embraer downgraded to Underperform from Outperform at Bradesco
04/09/20
Fly Intel: Top five analyst upgrades
ERJ Embraer
$5.52 /

+0.32 (+6.15%)

ERJ Embraer
$5.52 /

+0.32 (+6.15%)

ERJ Embraer
$5.52 /

+0.32 (+6.15%)

Recommendations
Karuna schizophrenia drug has blockbuster potential, says Stifel » 13:13
05/31/20
05/31
13:13
05/31/20
13:13
KRTX

Karuna Therapeutics

$94.26 /

+4.55 (+5.07%)

The full Phase 2 data for…

The full Phase 2 data for KarXT, presented over the weekend by Karuna Therapeutics, show a schizophrenia drug that is at least as effective as the standard-of-care but via a totally new mechanism and has a "much improved" tolerability profile than when studied in its prior iteration as xanomeline alone, Stifel analyst Paul Matteis tells investors in a research note. The full results show that for specific types of cholinergic adverse events - nausea, vomiting, dry mouth, constipation - reported rates on KarXT were considerably lower than observed in prior xanomeline trials, says the analyst. Matteis believes the totality of the data suggest that KarXT is "mostly derisked" as an antipsychotic drug and has blockbuster potential. The analyst has a Buy rating on the shares with a $126 price target. Karuna closed Friday up $3.74 to $93.86.

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

05/28/20 H.C. Wainwright
Karuna Therapeutics initiated with a Buy at H.C. Wainwright
05/08/20 Mizuho
Karuna Therapeutics price target raised to $116 from $103 at Mizuho
04/27/20 Oppenheimer
Karuna Therapeutics initiated with an Outperform at Oppenheimer
03/31/20
Fly Intel: Top five analyst initiations
KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

Hot Stocks
Taiwan Liposome announces topline results for TLC590 Phase II trial » 11:55
05/31/20
05/31
11:55
05/31/20
11:55
TLC

Taiwan Liposome

$4.84 /

+ (+0.00%)

TLC announced topline…

TLC announced topline results from the TLC590 Phase II clinical trial, a randomized, double-blind, placebo- and comparator- controlled study of TLC590 in patients following bunionectomy. Results show that TLC590 demonstrated greater reductions in pain than both placebo and bupivacaine through 168 hours. TLC590 is a non-opioid, proprietary BioSeizer sustained release formulation of ropivacaine. The trial compared TLC590 with normal saline placebo and the current standard of care for postsurgical pain relief, bupivacaine, in 150 patients randomized at the ratio of 1:1:1. The primary outcome measure was comparison of pain relief between TLC590, placebo, and bupivacaine in area under the curve on the numerical pain rating scale. The overall reduction in pain intensity provided by TLC590 was greater than that of placebo as well as bupivacaine at every time interval from 0 hours through the end of the study at 168 hours. TLC590 achieved statistically significant pain relief over both placebo from 0 to 24 hours. The differences in AUC0-72 did not reach statistical significance. TLC590 delayed the median time to first post-operative opioid use, and the total post-operative opioid consumption of TLC590 was less than both placebo and bupivacaine at every time point through 168 hours. TLC590 was well-tolerated, with a safety profile comparable to bupivacaine and placebo. Most adverse events were mild and unrelated to the treatment. There were no serious adverse events in the TLC590 group.

ShowHide Related Items >><<
TLC Taiwan Liposome
$4.84 /

+ (+0.00%)

TLC Taiwan Liposome
$4.84 /

+ (+0.00%)

12/23/19 Cantor Fitzgerald
Taiwan Liposome assumed with an Overweight at Cantor Fitzgerald
06/20/19 Baird
Taiwan Liposome initiated with an Outperform at Baird
Hot Stocks
Eli Lilly's CYRAMZA receives FDA approval for Metastatic EGFR-Mutated NSCLC » 11:52
05/31/20
05/31
11:52
05/31/20
11:52
LLY

Eli Lilly

$153.14 /

+2.51 (+1.67%)

Eli Lilly announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
04/24/20 Cantor Fitzgerald
Eli Lilly price target raised to $185 from $156 at Cantor Fitzgerald
04/24/20 Mizuho
Eli Lilly price target raised to $155 from $148 at Mizuho
04/21/20
Fly Intel: Top five analyst downgrades
LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

Conference/Events
American Society of Clinical Oncology (ASCO) to hold virtual meeting » 04:55
05/31/20
05/31
04:55
05/31/20
04:55
ABBV

AbbVie

$92.78 /

+2.77 (+3.08%)

, ALLO

Allogene Therapeutics

$48.08 /

+1.48 (+3.18%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

, ATNX

Athenex

$10.91 /

-0.21 (-1.89%)

, AVEO

Aveo Pharmaceuticals

$8.14 /

-1.08 (-11.71%)

, AZN

AstraZeneca

$54.60 /

+1.1 (+2.06%)

, BCYC

Bicycle Therapeutics

$17.50 /

-0.785 (-4.29%)

, BLUE

Bluebird Bio

$63.63 /

+2.82 (+4.64%)

, BPMC

Blueprint Medicines

$65.16 /

-1.84 (-2.75%)

, CGEN

Compugen

$15.50 /

+3.13 (+25.30%)

, HALO

Halozyme

$24.26 /

+0.79 (+3.37%)

, EXEL

Exelixis

$24.68 /

+0.35 (+1.44%)

, DCPH

Deciphera

$58.47 /

+1.53 (+2.69%)

, KURA

Kura Oncology

$17.09 /

+0.38 (+2.27%)

, KPTI

Karyopharm

$18.49 /

-0.31 (-1.65%)

, MRK

Merck

$80.85 /

+1.83 (+2.32%)

, BMY

Bristol-Myers

$59.72 /

-0.08 (-0.13%)

, MRSN

Mersana Therapeutics

$22.55 /

+2.85 (+14.47%)

, NXTC

NextCure

$31.20 /

-1.96 (-5.91%)

, PFE

Pfizer

$38.14 /

-0.03 (-0.08%)

, RECN

Changed to RGP

$0.00 /

+ (+0.00%)

, REPL

Replimune Group

$18.85 /

+0.3 (+1.62%)

, SBPH

Spring Bank Pharmaceuticals

$1.66 /

+0.015 (+0.91%)

, SGEN

Seattle Genetics

$157.30 /

+5.53 (+3.64%)

, STML

Stemline

$11.89 /

+ (+0.00%)

, SYRS

Syros Pharmaceuticals

$9.77 /

+0.25 (+2.63%)

, TRIL

Trillium Therapeutics

$6.76 /

+0.995 (+17.26%)

, TROV

Changed name to CRDF

$0.00 /

+ (+0.00%)

, XNCR

Xencor

$30.30 /

-0.69 (-2.23%)

Virtual Annual Meeting of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

05/22/20 Piper Sandler
Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
05/18/20 BofA
AbbVie reinstated with a Neutral at BofA
05/12/20 JPMorgan
AbbVie resumed with an Overweight from Neutral at JPMorgan
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

05/29/20 H.C. Wainwright
Allogene Therapeutics price target raised to $55 from $42 at H.C. Wainwright
05/29/20 Piper Sandler
Allogene Therapeutics price target raised to $70 from $50 at Piper Sandler
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
ATNX Athenex
$10.91 /

-0.21 (-1.89%)

12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
12/06/19 SunTrust
Athenex initiated with a Buy at SunTrust
11/19/19 RBC Capital
Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital
08/07/19 RBC Capital
Athenex's Oraxol data 'near best-case,' says RBC Capital
AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

05/29/20 Piper Sandler
Aveo Pharmaceuticals price target raised to $26 from $18.50 at Piper Sandler
05/29/20 Baird
Aveo Pharmaceuticals price target raised to $24 from $15 at Baird
05/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright
04/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 RBC Capital
Bluebird Bio initiated with an Outperform at RBC Capital
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
CGEN Compugen
$15.50 /

+3.13 (+25.30%)

05/26/20 JMP Securities
Compugen resumed with an Outperform at JMP Securities
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Stifel
Compugen initiated with a Buy at Stifel
05/07/20
Fly Intel: Top five analyst initiations
HALO Halozyme
$24.26 /

+0.79 (+3.37%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
05/06/20 Wedbush
Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush
KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
08/20/19 H.C. Wainwright
H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana
NXTC NextCure
$31.20 /

-1.96 (-5.91%)

05/29/20 Piper Sandler
NextCure data shows S15-mediated activity, says Piper Sandler
05/26/20 JMP Securities
NextCure initiated with an Outperform at JMP Securities
04/13/20 Piper Sandler
NextCure could report Phase I biomarker data at ASCO, says Piper Sandler
03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
RECN Changed to RGP
$0.00 /

+ (+0.00%)

01/03/20 Baird
Resources Connection Q3 guidance 'materially below' expectations, says Baird
10/03/19 JPMorgan
Resources Connection near-term outlook remains challenged, says JPMorgan
REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

04/02/20 Piper Sandler
Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow
01/29/20 Jefferies
Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies
01/29/20 Piper Sandler
Piper keeps Neutral rating on Spring Bank after inarigivir discontinued
12/30/19
Fly Intel: Top five analyst actions
SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 JMP Securities
Seattle Genetics initiated with an Outperform at JMP Securities
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/26/20 Goldman Sachs
Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs
STML Stemline
$11.89 /

+ (+0.00%)

05/05/20 H.C. Wainwright
Stemline downgraded to Neutral from Buy at H.C. Wainwright
05/05/20 Ladenburg
Stemline downgraded to Neutral from Buy at Ladenburg
05/04/20 Alliance Global Partners
Stemline downgraded to Neutral from Buy at Alliance Global Partners
05/04/20 Wedbush
Stemline downgraded to Neutral from Outperform at Wedbush
SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

05/29/20 Roth Capital
Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital
05/29/20 Piper Sandler
Syros price target raised to $14 after ASCO update at Piper Sandler
04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
03/06/20 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright
TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

05/26/20 JMP Securities
Trillium Therapeutics initiated with an Outperform at JMP Securities
08/19/19
Fly Intel: Top five analyst downgrades
08/19/19 H.C. Wainwright
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

01/28/20 Noble Capital
Trovagene resumed with an Outperform at Noble Capital
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

XNCR Xencor
$30.30 /

-0.69 (-2.23%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

Periodicals
Bae Systems stock should be on investors' radar, Barron's says » 11:47
05/30/20
05/30
11:47
05/30/20
11:47
BAESY

BAE Systems

$0.00 /

+ (+0.00%)

BAE Systems is one of the…

BAE Systems is one of the few companies to come out of the first quarter unscathed by COVID-19. making the defense contractor a defensive play, Rupert Steiner writes in this week's edition of Barron's. Reference Link

ShowHide Related Items >><<
BAESY BAE Systems
$0.00 /

+ (+0.00%)

BAESY BAE Systems
$0.00 /

+ (+0.00%)

05/18/20 UBS
BAE Systems price target lowered to 511 GBp from 700 GBp at UBS
04/29/20 JPMorgan
BAE Systems price target lowered to 765 GBp from 775 GBp at JPMorgan
04/29/20 JPMorgan
BAE Systems shares offer 50% upside potential, says JPMorgan
04/27/20 Morgan Stanley
BAE Systems upgraded to Overweight from Equal Weight at Morgan Stanley
BAESY BAE Systems
$0.00 /

+ (+0.00%)

BAESY BAE Systems
$0.00 /

+ (+0.00%)

Periodicals
Cheniere Energy Partners looks like a buy, Barron's says » 11:43
05/30/20
05/30
11:43
05/30/20
11:43
CQP

Cheniere Energy Partners

$33.91 /

+0.87 (+2.63%)

It is rare for an energy…

It is rare for an energy company to increase its dividend in the current environment, and it's even rarer for a company to have done it twice in the past six months, even in the face of the largest economic shock since the Great Depression, Avi Salzman writes in this week's edition of Barron's. Cheniere Energy Partners (CQP) has bucked the larger trends in energy this year, repeatedly raising its payout even as the broader industry buckles, he notes, adding that the company's stock is down more than 30% from its 2019 highs, and now yields 7.7%. That opens up an opportunity for yield-hungry investors, the author contends. Reference Link

ShowHide Related Items >><<
CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

03/24/20 Barclays
Cheniere Energy Partners upgraded to Overweight from Equal Weight at Barclays
03/12/20 Credit Suisse
Cheniere Energy Partners upgraded to Neutral from Underperform at Credit Suisse
03/05/20 UBS
Cheniere Energy Partners upgraded to Buy from Neutral at UBS
02/26/20 Odeon Capital
Cheniere Energy Partners upgraded to Buy from Hold at Odeon Capital
CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

Periodicals
Marathon among stocks to buy as Americans get back on the road, Barron's says » 10:32
05/30/20
05/30
10:32
05/30/20
10:32
VLO

Valero

$66.62 /

-0.59 (-0.88%)

, MPC

Marathon Petroleum

$35.13 /

-0.08 (-0.23%)

, PSX

Phillips 66

$78.30 /

-0.35 (-0.45%)

Driving is rebounding as…

Driving is rebounding as the economy reopens and Americans take to their cars, viewing them as being more protected spaces than airplanes, trains, or other mass transit, Andrew Bary writes in this week's edition of Barron's. That looks bullish for Marathon Petroleum (MPC) and other big refining stocks, such as Valero Energy (VLO) and Phillips 66 (PSX), that have bounced off their March lows, but are still down an average of 30% this year, the analyst notes. Reference Link

ShowHide Related Items >><<
VLO Valero
$66.62 /

-0.59 (-0.88%)

PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

VLO Valero
$66.62 /

-0.59 (-0.88%)

05/21/20 US Capital Advisors
Valero downgraded to Overweight from Buy at US Capital Advisors
05/13/20 Morgan Stanley
U.S. gasoline consumption appears to have bottomed, says Morgan Stanley
05/04/20 Mizuho
Mizuho upgrades Valero, Phillips 66 and HollyFrontier to Buy from Neutral
05/04/20 Mizuho
Valero upgraded to Buy from Neutral at Mizuho
MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

04/24/20 Citi
Marathon Petroleum downgraded to Neutral from Buy at Citi
03/24/20 Raymond James
Marathon Petroleum double downgraded to Market Perform at Raymond James
03/24/20 Raymond James
Marathon Petroleum downgraded to Market Perform from Strong Buy at Raymond James
PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

05/21/20 US Capital Advisors
Phillips 66 downgraded to Overweight from Buy at US Capital Advisors
05/13/20 Wolfe Research
Phillips 66 downgraded to Peer Perform from Outperform at Wolfe Research
VLO Valero
$66.62 /

-0.59 (-0.88%)

PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

VLO Valero
$66.62 /

-0.59 (-0.88%)

PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

VLO Valero
$66.62 /

-0.59 (-0.88%)

PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

Periodicals
Southwest, Spirit could benefit from pickup in domestic travel, Barron's says » 10:30
05/30/20
05/30
10:30
05/30/20
10:30
DAL

Delta Air Lines

$25.19 /

-0.47 (-1.83%)

, SAVE

Spirit Airlines

$12.96 /

+0.035 (+0.27%)

, LUV

Southwest

$32.11 /

-0.44 (-1.35%)

Airlines have bolstered…

Airlines have bolstered their balance sheets, they are luring nervous fliers by deep-cleaning planes and increasing distance between strangers, and they are limiting ticket sales per flight and letting passengers rebook if the dreaded middle seat is all that's left, Daren Fonda writes in this week's edition of Barron's. It seems to be working, the author notes, adding that while the airline stocks aren't the deep-value plays they were a few weeks ago, the sector is still off 55% from its 52-week high and there is probably more upside if there isn't another wave of infections. Southwest Airlines (LUV) looks like the safest bet in the sector, Fonda contends, highlighting also Spirit Airlines (SAVE) and Delta Air Lines (DAL). Reference Link

ShowHide Related Items >><<
SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
Delta Air Lines downgraded to Equal Weight from Overweight at Barclays
04/23/20 Raymond James
Delta Air Lines price target lowered to $36 from $40 at Raymond James
04/21/20 Deutsche Bank
Delta Air Lines price target lowered to $47 from $51 at Deutsche Bank
SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

05/29/20 Wolfe Research
Spirit Airlines downgraded to Underperform from Peer Perform at Wolfe Research
05/18/20 Evercore ISI
Spirit Airlines upgraded to Outperform from In Line at Evercore ISI
05/13/20
Fly Intel: Top five analyst downgrades
05/13/20 Raymond James
Spirit Airlines downgraded to Market Perform from Outperform at Raymond James
LUV Southwest
$32.11 /

-0.44 (-1.35%)

05/26/20
Fly Intel: Top five analyst upgrades
05/26/20 UBS
Southwest upgraded to Buy from Neutral at UBS
05/19/20 Goldman Sachs
Southwest, United seeing modest improvements in demand, says Goldman Sachs
SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

Periodicals
Extended Stay could emerge a winner, Barron's says » 10:26
05/30/20
05/30
10:26
05/30/20
10:26
HLT

Hilton

$79.37 /

-1.26 (-1.56%)

, MAR

Marriott

$88.48 /

-3.14 (-3.43%)

, STAY

Extended Stay America

$11.50 /

+0.17 (+1.50%)

The summer travel season…

The summer travel season will look different this year, but that doesn't mean there isn't value to be found among hotel stocks, Carleton English writes in this week's edition of Barron's. Extended Stay America (STAY) shares are down 24% this year-worse than the S&P 500 index, which is off 6%, but better than hotel stocks like Marriott International (MAR) and Hilton Worldwide Holdings (HLT), down 39% and 27%, respectively, the author notes, arguing that Extended Stay stock has room to run. Reference Link

ShowHide Related Items >><<
STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

MAR Marriott
$88.48 /

-3.14 (-3.43%)

HLT Hilton
$79.37 /

-1.26 (-1.56%)

HLT Hilton
$79.37 /

-1.26 (-1.56%)

05/11/20 Raymond James
Hilton price target raised to $82 from $77 at Raymond James
05/08/20 Deutsche Bank
Hilton price target lowered to $74 from $103 at Deutsche Bank
04/22/20 BofA
Choice Hotels upgraded to Neutral from Underperform at Bofa
04/14/20 Barclays
Investors should start preparing to buy lodging stocks, says Barclays
MAR Marriott
$88.48 /

-3.14 (-3.43%)

05/12/20 BMO Capital
Marriott price target raised to $74 from $65 at BMO Capital
05/12/20 Deutsche Bank
Marriott price target lowered to $88 from $124 at Deutsche Bank
05/12/20 Morgan Stanley
Marriott estimates cut at Morgan Stanley following Q1 report
STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

04/22/20
Fly Intel: Top five analyst upgrades
04/22/20 Jefferies
Jefferies upgrades Extended Stay America to Buy, doubles price target to $14
04/22/20 Jefferies
Extended Stay America upgraded to Buy from Hold at Jefferies
STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

MAR Marriott
$88.48 /

-3.14 (-3.43%)

HLT Hilton
$79.37 /

-1.26 (-1.56%)

STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

MAR Marriott
$88.48 /

-3.14 (-3.43%)

HLT Hilton
$79.37 /

-1.26 (-1.56%)

STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

MAR Marriott
$88.48 /

-3.14 (-3.43%)

HLT Hilton
$79.37 /

-1.26 (-1.56%)

MAR Marriott
$88.48 /

-3.14 (-3.43%)

HLT Hilton
$79.37 /

-1.26 (-1.56%)

Periodicals
Lindblad Expeditions could weather COVID-19 storm, Barron's says » 10:19
05/30/20
05/30
10:19
05/30/20
10:19
LIND

Lindblad Expeditions

$7.87 /

+0.2 (+2.61%)

Lindblad Expeditions may…

Lindblad Expeditions may offer investors an alternative to the cynical view of cruise ships as "floating petri dishes," Alexandra Scaggs writes in this week's edition of Barron's. The company specializes in "adventure cruises" to Antarctica, the Amazon rainforest, and Patagonia, to name a few pricey destinations, and its shares have been dragged down-by 53%, year to date-along with those of other cruise operators, the author notes. But with some careful cash management, Lindblad could come out of the shutdown stronger than the large cruise operators, Scaggs contends. Reference Link

ShowHide Related Items >><<
LIND Lindblad Expeditions
$7.87 /

+0.2 (+2.61%)

LIND Lindblad Expeditions
$7.87 /

+0.2 (+2.61%)

04/28/20 Stifel
Lindblad demand should return faster than 'normal' cruises, says Stifel
04/22/20 Deutsche Bank
Lindblad Expeditions price target lowered to $7 from $16 at Deutsche Bank
04/13/20 Sidoti
Lindblad Expeditions downgraded to Neutral from Buy at Sidoti
03/25/20 Sidoti
Lindblad Expeditions upgraded to Buy from Neutral at Sidoti
LIND Lindblad Expeditions
$7.87 /

+0.2 (+2.61%)

LIND Lindblad Expeditions
$7.87 /

+0.2 (+2.61%)

Periodicals
Time to buy insurance stocks, Barron's says » 10:15
05/30/20
05/30
10:15
05/30/20
10:15
HIG

Hartford Financial

$38.37 /

-0.205 (-0.53%)

, CB

Chubb

$122.01 /

-1.69 (-1.37%)

Investors tend to dump…

Investors tend to dump insurance stocks at the height of a catastrophe, fearing how large losses will get, but history suggests they should be buying instead, Al Root writes in this week's edition of Barron's. Chubb (CB) and Hartford Financial (HIG) are trading below historical multiples of earnings and book value, and both P&C insurers have strong balance sheets and a history of growth, the author contends. Reference Link

ShowHide Related Items >><<
HIG Hartford Financial
$38.37 /

-0.205 (-0.53%)

CB Chubb
$122.01 /

-1.69 (-1.37%)

HIG Hartford Financial
$38.37 /

-0.205 (-0.53%)

05/05/20 Deutsche Bank
Hartford Financial price target lowered to $53 from $63 at Deutsche Bank
04/14/20 Morgan Stanley
Hartford Financial upgraded to Overweight from Equal Weight at Morgan Stanley
04/08/20 RBC Capital
Hartford Financial price target lowered to $39 from $66 at RBC Capital
04/01/20 Wells Fargo
Hartford Financial upgraded to Overweight from Equal Weight at Wells Fargo
CB Chubb
$122.01 /

-1.69 (-1.37%)

04/24/20 Raymond James
Raymond James downgrades Travelers to Underperform on COVID-19 impact
04/23/20 Wells Fargo
Chubb price target lowered to $142 from $150 at Wells Fargo
04/22/20 MKM Partners
Chubb price target lowered to $145 from $170 at MKM Partners
04/13/20 Deutsche Bank
Chubb upgraded to Hold from Sell at Deutsche Bank
HIG Hartford Financial
$38.37 /

-0.205 (-0.53%)

CB Chubb
$122.01 /

-1.69 (-1.37%)

HIG Hartford Financial
$38.37 /

-0.205 (-0.53%)

HIG Hartford Financial
$38.37 /

-0.205 (-0.53%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.